Procter & Gamble’s pricing strategy now impacts 10 of its US product categories, with action also being taken broadly in non-US markets. President and CEO Jon Moeller calls this pricing "at a different level" historically speaking, and warns there will be ‘bumps in the road." But P&G is confident in its long track record and raises full-year guidance accordingly.
Procter & Gamble is hiking product prices across the globe, targeting 60% to 70% of its total portfolio as it continues to battle commodity cost increases and never-before-seen volatility “across the geopolitical spectrum,” according to president and CEO Jon Moeller.
Moeller announced the expanded pricing strategy, which will implement mid-single-digit increases, during P&G’s earnings briefing on 19 January for its...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
